Quanterix introduced the Simoa APOE Proteotyping Advantage PLUS Kit, which brings APOE4 carrier determination into the same plasma biomarker workflow with no separate genotyping step and no additional sample type.
Published
Signal category
Products & Services
Quote
“A new approach to APOE4 carrier determination is now available.”
— Quanterix team
Company
Quanterix
Powering Biomarkers from Discovery to Diagnostics
- Industry
- Biotechnology Research
- Location
- Billerica, US
- Company size
- 509 employees
Quanterix is a global leader in precision biomarker science, making biology measurable to deliver earlier insights and support breakthroughs in disease research, diagnostics, and drug development. Its Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. Through the acquisition of Akoya Biosciences, Quanterix Spatial solutions deliver high-plex, quantitative protein analysis in tissue at single-cell resolution. Combined with Accelerator Laboratory services, Quanterix gives researchers the tools and expertise to translate discovery into precision diagnostics. Learn more at www.quanterix.com.
Founded 2007